Philipp Spycher, Araris CEO

Promis­ing bet­ter link­er tech to ADC field, Araris has 'very, very am­bi­tious' plans for the clin­ic

A cou­ple months af­ter rais­ing CHF 2.5 mil­lion ($2.76 mil­lion) in ini­tial seed fund­ing, one-year-old Araris Biotech is top­ping off the round with an­oth­er CHF 12.7 mil­lion ($14 mil­lion).

The Paul Scher­rer In­sti­tute and ETH Zurich spin­out now has CHF 15.2 mil­lion to work with, and CEO Philipp Spy­cher has big plans. He hopes to bring one of the com­pa­ny’s an­ti­body-drug con­ju­gates (ADC) to the clin­ic by late 2022 or ear­ly 2023. “It’s very, very am­bi­tious, but we are very op­ti­mistic that we ac­tu­al­ly can make it,” he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.